The Menopause Conversation Your GP Probably Skipped — And the 2022 Guidelines That Changed Everything

Bottom line: For 20 years, HRT was prescribed with deep caution based on a flawed 2002 study. The 2022 Menopause Society position statement reversed this: HRT is appropriate and beneficial for most healthy women under 60 within 10 years of menopause, and the risks are substantially smaller than the original guidance suggested. Most GPs haven’t updated their prescribing practice to reflect this. Here’s what the current evidence actually says — and how to access a physician who has read the 2022 guidelines.

---

The Study That Got It Wrong — and How It Changed Women’s Healthcare

In 2002, the Women’s Health Initiative (WHI) published a landmark trial that appeared to show HRT increased the risk of breast cancer, heart disease, and stroke. GP prescribing of HRT dropped by 50% within two years. A generation of menopausal women was undertreated — told that hot flashes, insomnia, and joint pain were normal aging, not addressable symptoms.

The problem: the WHI study had a fundamental design flaw.

The average age of participants was 63. The average time since menopause was 12 years. The women were largely in the “late transition” window — which the timing hypothesis indicates has a materially different risk profile than starting HRT within 10 years of menopause onset.

In essence, the WHI was studying what happens when you give HRT to women who had already gone 10–12 years without it — not what happens when you give it to women in their 50s experiencing active menopausal symptoms.

Subsequent re-analyses disaggregated the data by age and timing. When the data was isolated to women under 60 who started HRT within 10 years of menopause, the cardiovascular and breast cancer risk signals largely disappeared or reversed. For this population, HRT appeared to be cardioprotective — reducing cardiovascular disease risk compared to not taking it.

Is HRT safe for menopausal women under 60?

The 2022 Menopause Society position statement concluded yes: HRT benefits outweigh risks for most healthy women under 60 within 10 years of menopause onset. The breast cancer risk with combined HRT is small in absolute terms — comparable to the risk from drinking 1–2 glasses of wine daily. Bioidentical progesterone shows a lower risk profile than the synthetic progestins used in the original WHI study.

---

What Your GP May Not Have Told You

The standard consultation problem: The average GP has 10–15 minutes for a routine appointment. Menopause counselling requires discussing symptom severity, risk factors, HRT type options, alternative approaches, and patient preferences. This can’t be done well in 12 minutes alongside the rest of an appointment. The result is that many GPs default to conservative prescribing, telling patients their symptoms are “normal” and “it will pass.”

The 2022 guidelines are not widely implemented: Medical guidelines take 5–10 years to fully penetrate GP practice. The 2022 Menopause Society update is among the most significant revisions in women’s health in decades — but the physicians who trained in the post-2002 period of HRT restriction often haven’t updated their clinical practice to match the new evidence.

The specialist referral problem: GPs who don’t want to manage HRT prescribing may refer to a gynaecologist. Specialist wait times in the US and UK are 3–9 months for routine referrals. Women with active moderate-to-severe symptoms are living through that wait with no treatment.

---

The Four Symptoms That HRT Directly Addresses

The evidence is strongest for these four categories:

Hot flashes and night sweats: 70–90% reduction in frequency with estrogen therapy, per multiple meta-analyses. This is the most robustly supported HRT benefit.

Sleep disruption: Two mechanisms — progesterone directly improves sleep architecture through GABA agonism; estrogen therapy addresses night sweats that fragment sleep secondarily.

Genitourinary symptoms (vaginal dryness, painful sex, urinary changes): These are caused by estrogen depletion in urogenital tissue. HRT reverses or substantially improves these symptoms — which get progressively worse over time if untreated, unlike vasomotor symptoms which naturally diminish.

Bone density: Estrogen is critical to osteoblast activity. Menopause accelerates bone loss; HRT prevents this acceleration. Women who delay HRT by 10 years lose significant bone density that cannot fully be recovered.

---

What the Non-Hormonal Alternatives Actually Do

There are legitimate non-hormonal options for women who cannot take HRT (active hormone-sensitive cancer, specific cardiovascular history):

SSRIs/SNRIs: Reduce hot flash frequency by 30–50% (compared to 70–90% with HRT). Side effects include sexual dysfunction and weight changes.

Fezolinetant (Veozah): A selective NK3 receptor antagonist approved in 2023 that reduces hot flash frequency by 50% on average. Non-hormonal, prescription required. No direct effect on genitourinary or bone symptoms.

Phytoestrogens (soy, black cohosh): Evidence for hot flash reduction is inconsistent; best estimates are 10–20% reduction in frequency. Safe, but substantially less effective than HRT.

These options matter for women with specific contraindications. For women without contraindications, the 2022 evidence strongly supports HRT as first-line.

---

Accessing HRT Without a 6-Month Wait

Winona is a telehealth platform that provides physician consultation and bioidentical HRT prescription without requiring a specialist referral or in-person appointment. The intake process reviews your full medical history; the prescribing physician applies the 2022 Menopause Society guidelines to your specific profile.

For women who’ve been told by their GP to “just manage through it” or wait months for a specialist, Winona offers a 24–48 hour turnaround from intake to prescription.

[For the first-person 90-day experience on Winona HRT, see our full Winona HRT review.] [For the perimenopause symptoms that precede menopause and often go unrecognized, see our perimenopause early signs guide.]

---

Access Winona HRT → Licensed Physician, No Referral Required

This article contains affiliate links. Verto earns a commission if you start a Winona program through our link. HRT is a prescription treatment — physician consultation determines eligibility. This article reflects evidence-based guidelines and is not individual medical advice. Always discuss your specific situation with a healthcare provider.